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Our relationship to infectious pathogens is
part of an evolutionary drama (1). Here we are;
here are the bugs. They are looking for food; we
are their meat. How do we compete? They
reproduce so quickly, and there are so many of
them. They tolerate vast fluctuations of
population size as part of their natural history; a
fluctuation of 1% in our population size is a major
catastrophe. Microbes have enormous potential
mechanisms of genetic diversity. We are different
from them in every respect. Their numbers, rapid
fluctuations, and amenability to genetic change
give them tools for adaptation that far outpace
what we can generate on any short-term basis.
So why are we still here? With very rare
exceptions, our microbial adversaries have a
shared interest in our survival. With very few
exceptions (none among the viruses, a few among
the bacteria, perhaps the clostridial spore-
forming toxin producers), almost any pathogen
reaches a dead end when its host is dead. Truly
severe host-pathogen interactions historically
have resulted in elimination of both species. We
are the contingent survivors of such encounters




Microbial intraclonal methods of variation
are legion. DNA replication is error prone, and
often the constraints of precise replication are
turned off in the presence of DNA damage or other
injury. Microbes often live in a sea of mutagens,
chemical and physical. If we go out in the sun, our
skin is damaged; in microbes, UV irradiation goes
unimpeded to the very core of their DNA. Those
that are not killed are rapidly mutated.
RNA Replication
RNA replication is particularly error prone.
There are no editing mechanisms for examining
the fidelity of replication; therefore, the concept
of the quasispecies swarm was recently gener-
ated. For many RNA viruses, retroviruses in
particular, the rates of mutation are so high that
to a close approximation, every particle is
genetically different (in at least one nucleotide)
from every other particle. They are rapidly
evolving as swarms of genotypes, no single
genotype being totally representative. Natural
selection plays a substantial role. The role of
cooperativity in infection of these viruses,
particularly among retroviruses and HIV, has not
been adequately investigated. Rous sarcoma
virus is a case in point. It may be difficult for a
single particle, many generations removed from
the original competent infector, to consummate
an infection by itself, but it can be complemented
by other helper viruses present in the same cell.
Haploid Organisms
Most of the organisms we are dealing with are
haploid, so they have no delay in expressing new
genetic factors. The prompt expression may
potentially augment cumulative genetic alter-
ations, but in the short run, a resistance mutation
will manifest itself almost immediately and will
be subject to natural selection very promptly.
Multicopy plasmids, which would behave differ-
ently, are exceptions.
Phase Variation
Phase variation occurs in almost every
pathogenic bacterium, in malaria parasites, in
trypanosomes, and in Borrelia. Changes that
appear to be mutational, on closer examination
turn out to be microbial access to an archive of
genetic information, much of which has been
silenced and then reappears as an adaptive
change. The flagellar antigens of salmonella
provide the historic example; they can exist in
either so-called specific phase or group phase,
going back to H1 or H2 loci. We now know that
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the position of a piece of DNA that can be inverted
to move the promoter from one locus to another
and give a very sudden transformation of the
serotype from type 1 to type 2. This is a
completely reversible phenomenon; the same
event can reinvert that DNA. Many species of
site-specific recombinases are capable of scram-
bling and rescrambling the bacterial genome in
order to silence and unsilence genes that may be
then carried in an archival state. I pondered why
bugs use this mechanism for keeping genes in a
cryptic state when gene expression can be (and
often is) regulated in other ways. The simplest
speculation is that phase variation very often
entails controlled antigenic factors. A bug does
not want to telegraph to its host in advance that it
is carrying even a tiny relic of an alternative
epitope because that will provoke immunity on
the part of the host even before it has undergone
that phase variation.
Genetic factors also control the rates of
mutability; whether these factors do or do not
directly influence adaptability to virulence is
controversial. Preliminary reports suggested
that virulent bacteria had a higher incidence of
mutators. We now realize that mutators are quite
prevalent, and therefore bacteria are constantly
facing environmental challenges.
Interclonal Processes
Recombination mechanisms are quite pro-
miscuous. Conjugation, which can occur between
bacteria of widely varying kinds, is most often
recognized by plasmid transfer and every now
and then by mobilization of chromosomes.
Conjugation can even occur across kingdoms,
between a bacterium and a yeast, or between a
bacterium and a plant. In the case of the
rhizobium-like parasite, the crown gall bacte-
rium, genetic material is transferred from the
bacterium into the chromosomes of the host
plant. Similar phenomena probably occur in
eukaryotic infections. Some genes in viruses and
bacteria almost certainly were of eukaryotic
origin. Some bacteria can deliver DNA intercellu-
larly to their host animals.
Plasmid interchange (movement of tiny bits
of DNA from one species to another) is not just a
laboratory curiosity; it is the mechanism for rapid
spread of antibiotic resistance from widely
different species, one to another. It adds even
greater cogency to our concerns about the less
than optimally advantageous use of antibiotics
(e.g., in animal husbandry). The mechanisms
exist to make it easy not only for single antibiotic
resistance but whole blocks of resistance to be
moved from one bacterium to another.
Host-Parasite Coevolution
Microbes’ shared interest in our survival will
dominate the overall picture of their evolution.
Can this help us predict the outcome of the
balance between the host and the pathogen? The
possible outcomes are so divergent that it is very
difficult to predict in detail what is going to
happen in any particular confrontation.
The long-term trend is coadaptation, in which
the host acquires factors for resistance and the
parasite acquires factors for mitigation and
longer survival of (and thereby in) the host. These
factors may be genetic mutations, which will
certainly be selected.
Other factors include human cultural
changes, such as hygienic procedures. The
human species outdoes all other species in
adopting behavior that is self-destructive rather
than self-protective. I am not convinced that
every nuance of human behavior has been
specifically evolved. Most of our behavior, even
the maladaptive self-destructive kind, is learned:
the pity and the hope of our species.
Pathogens find it to their advantage to
mitigate their virulence, provided they can do so
without compromising their livelihood. That is
the tightrope they walk. Rhinovirus, the agent of
the common cold, is an extremely successful
pathogen. We do little to get rid of it. We go to
work and school with our runny noses. The virus
has a number of adaptations (including the very
moderation of its disease process) that tend to
facilitate its spread. I worry that a rhinovirus
may some day mutate into a somewhat more
virulent form, given that it is capable of very
rapid spread.
Evolutionary Strategies
The parasite’s dilemma is that if it
proliferates rapidly, it may kill the host; that
would be a winning strategy if transmission were
easy, vectors readily available, the host’s
behavior obliging, and mosquitoes abundant for
high-density spread. Such circumstances are
present in northwest Thailand where Plasmo-
dium falciparum would be unlikely to survive for
very long (because of its profound effects on its
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not favorable. In modern hospitals, the
mosquitoes are health-care attendants who
inadvertently facilitate the transfer of infection
from one patient to another.
Toxins
It is a wonder that the inexhaustible
reservoir of potent toxins has not spread much
further. Botulinum toxin, one of the deadliest
compounds, is produced in abundance by
Clostridium botulinum, whose spread to other
organisms and potential for becoming a major
public health threat can easily be imagined. Why
is this toxin so confined? The underlying biologic
mechanisms are not confining it; rather, its
lethality keeps it under control. The microbe kills
its host rapidly, and if it cannot continue to multiply
even in the dead host, it reaches a dead end.
In specific physiologic circumstances, these
rules of natural selection might not apply.
Escherichia coli O157 is a case in point. O157 has
little to do with E. coli; it is a shigella with a little
cloak of E. coli antigens. O157 should not be used
as the sole diagnostic criterion for the spread of
shigelloid disease. The toxin genes can inhabit
other vectors. The ecologic implications of its
human and bovine virulence are not clear.
Perhaps polymorphism (changes in bacterial
genotype) alters its virulence in human and bovine
species. The human loop is quite incidental to its
overall survival, as far as we know. The attack rate
in humans is only 1%. How has E. coli O157
evolved? We understand that as poorly as we
understand the sporadic emergence of Legionella
from the soil into our air-conditioner ducts.
Proliferation Rate
If the parasite adopts another strategy and
proliferates slowly, we have an evolutionary
mechanism in which our own immune system is
looking for deviants; this mechanism will be
presenting new epitope receptors waiting to be
stimulated. Most acute infections produce a full
immune response at a humoral and a cellular
level within a week or 10 days. So the microbe
that proliferates slowly is laying the groundwork
for its own vulnerability unless it adopts some
further tactics (e.g., phase variation, stealth
tactics, antigenic mimicry, exploiting the
autotolerance that the host needs to survive its
own immune system). Parasites also compete
with commensals, with probiotic organisms. This
is where HIV runs into severe trouble. Left to its
own devices, HIV would not kill its host; but by
knocking down the host’s immune system, the
virus opens the door for other organisms,
including commensals, opportunists that can
thrive only when the immune defenses are
attenuated.
Symptoms
Vectors are rarely symptomatic, almost never
severely symptomatic. The plasmodium would
not benefit from killing the mosquitoes that
transmit it. If a rabid dog can be considered a
vector, its behavioral anomaly illustrates another
adaptation that serves the purposes of the
parasite.
This line of thinking, what some people have
called evolutionary medicine—call it common
sense—leads us to look at symptoms. To what
extent should we be treating them? Some we
treat because they are life-threatening. But is
fever, for example, a host defense? Is it a mode of
bacterial attack? Is the bacterium or virus
producing pyrogens because a higher tempera-
ture will promote its own replication? Are
pyrogens just side effects of other evolutionary
adaptations that have not come to equilibrium? It
is hard to avoid models that assume equilibrium;
few complex physiologic systems are so obliging.
We should question symptoms from an evolution-
ary perspective. How did they come to be there?
This approach may open the door to new avenues
of thought in examining the disease process.
Cough, diarrhea, or hemorrhage may serve the
purposes of the parasite; even so, we may still have
to treat hemorrhage, but how far should we go in
treating cough? On the one hand, if not too severe,
cough may eliminate some of the infectious load
from the body; on the other hand, cough generates
an aerosol that further disseminates the organism.
Cough may have to be treated as a public health
measure as much as a therapeutic measure.
Diarrhea is another example; it may be a way of
eliminating the parasite or a special adaptation
enhancing dissemination.
Other symptoms (malaise, headache, pain,
itching) probably have different answers. Pain is
a puzzling symptom, which plays an indispens-
able role by drawing attention to a disease. Once
the disease is acknowledged, there is no reason in
the world not to treat pain. Yet I know of no
infection (other than chronic leprosy) that
induces anesthesia. It would seem to me that a
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euphoria (rather than pain) to its host; we would
welcome it and infect ourselves with it. Analgesia
may be the eventual moral hazard of biotechnology,
the internalized moonshine still or poppy patch.
The ultimate symptom, death of the host, is
almost never to the advantage of the parasite.
Death signals a breakdown in the equilibrium
(the contract between parasite and host) that
could have had a better outcome had both sides
been more witting.
Zoonotic Interactions
Many lessons of evolutionary relationships
come from zoonotic interactions. Infections that
break out of their host of origin often have a very
severe impact on their new host. Hantavirus is an
outstanding recent example. The pathologic
processes in the rodent carriers hardly compare
with those in humans. Most zoonotic transfers
simply do not work. They are host specific; many are
neutral. Every now and then, a zoonotic transfer
has enormously larger pathologic implications for
the host; these are the transfers we focus on. We
presume that the filoviruses and perhaps HIV are
in that category. Many, not all, simian immunodefi-
ciency viruses are perceptibly less virulent in their
natural host than HIV is in humans, perhaps
another example of equilibrium breakdown.
How could the zoonoses be pathogenic when
they require so many subtle adaptations to come
into a host and really cause disease? Dozens, if
not hundreds, of bacterial genes would have to
work in concert to be pathogens. Microbes make
proteins and carbohydrates, familiar to our
systems of immunity. Therefore, if the parasite
does not know how to live in the earthly host and
the host cannot cope with totally alien parasites,
we end up with a wash.
Consider tsutsugamushi fever, scrub typhus.
Bangkok is reporting intermediate levels of drug
resistance in Orientalia in tsutsugamushi in
central and eastern Thailand. The life cycle is one
of essentially a hereditary symbiont; the tick is
transmitted transovarially and can be communi-
cated from tick to microbe or humans, where it
rapidly proliferates. Reinfection back to the tick
is not of consequence, which must be a fairly
recent spillover of pathogenicity for which there
is not ongoing selection. Nothing in the life
history of Orientalia would sustain its pathoge-
nicity to maintain its high infectivity.
Years ago planetary quarantine became a
policy consideration, beginning with Sputnik in
the late 1950s and the early planning of our space
program. Would it be permissible to move
contaminated spacecraft from one planet to
another? Certainly proliferating organisms on
Earth could be easily carried to Mars. What
would happen if we brought back Mars samples?
These considerations resulted in an international
convention for the conservation of the microbial
virginity of celestial bodies. Sterilization proto-
cols were applied to the Viking Mars spacecraft
and by the Russians in the 1970s.
Maternal Immunity
One mechanism of accommodation is not
genetic but physiologic: maternal immunity. The
recent outbreak of canine distemper in the lions
of the Serengeti (1) demonstrates a
quasihereditary cycle that does not involve the
genes at all but rather is the propagation of
maternal immunity, partial immunity on the
part of the offspring, easier adaptation to
infection by the host.
Mitochondria—the Ultimate Pathogens
What are the ultimate pathogens, the
ultimate symbionts? The mitochondria. A
bacterial invader probably 2.5 billion years ago
got into the first eukaryotic cells and conferred
oxidative machinery. Who is serving whom? We
generally think mitochondria are to our
advantage, but think how hard we work to shovel
the coal into the furnace that the mitochondria
have provided in every cell of our body. Symbiosis
is a fact of life, not always friendly or mutually
accommodating. In bacteria, plasmids confer
great advantages for some functions, but many
plasmids also convey a “leave me and you die”
message. The plasmid encodes simultaneously
for a toxin and an antitoxin but makes sure that
the toxin has a longer lifespan. So a bacterium
careless enough to drop its plasmid will suffer.
The plasmid has the long-term advantage of
ensuring that only cells able to continue to
proliferate will continue to have the plasmid. So
knowing who is serving whom in these kinds of
relationships is very complicated.
Patterns of Evolution
Thanks to the wonders of genomics and DNA
analysis, we have a good overall model of the tree
of life and the overall patterns of evolution. By
the criterion of 16S RNA, extraordinary
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multicellular branch, but these changes are not
at the level of fundamental housekeeping
machinery; they have to do with growing brains,
eyes, branches, and flowers, incidental items not
at the level of cellular physiology.
Viruses
Where do viruses come from? Certainly in the
world of eukaryotic viruses, no one can say with
confidence what the evolutionary provenance is.
We believe that viruses originated from some
kind of cellular organelle, perhaps ultimately
from the nuclear DNA, perhaps from the other
organelles. Many of them would have to have
undergone enormous changes, and we cannot say
which came from where in any tangible example.
This complexity can be illustrated (in the
prokaryotic systems) by the ease with which viral
genomes can be integrated into bacterial chromo-
somes. These are all double-stranded DNA
bacterial viruses, so they have the same
fundamental structure as bacterial chromosomes.
They go in and out with ease and can be integrated
and  mobilized, sometimes as viruses, sometimes
as bacterial genes. It is impossible to say which
came first. If one could point to an evolutionary
progression of clusters of genes in a bacterium on
the way to generation of a new virus, it would be
of some help, but how would one know it was not
the relic of a very old one coming back again? Our
most fundamental knowledge is very primitive.
Prions
Prions offer a new paradigm, much of which
we do not understand. Stan Prusiner has argued
that prions are pure proteins. Trying to
understand how a pure protein can propagate
confounds our conceptions of the transmission of
biological information. So let us say that prion
protein (e.g., scrapie prion protein) is a
conformational modification of a normal protein,
prp-c, coded for by an endogenous gene, a part of
the normal genome, not an essential gene.
Infected mice show some functional disorders but
can survive. One might argue that we do worse
with this gene than without it as long as we are
susceptible to this modification.
Not much new sequence information is
imparted to the normal prion to convert it to the
infective agent. The change may be merely in
the prion’s conformation. We must consider
other mechanisms that might cause that same
conversion.
The rare nonfamilia incidence of sporadic
Creutzfeldt-Jakob disease (CJD) poses a possible
example, although it is difficult to exclude some
contact with prions in individual cases. We might
watch for CJD-like disease as an incident to other
kinds of toxic insults. One implication of the
protein-prion model, not discussed hitherto, is
that conformer alterations may ensure from
chemical or physical trauma to preexisting prp-c;
heat, toxins, side effects of other infections are
candidates (2). Let us carefully label this as wild
speculation, pending badly needed assays for this
conformer-altering capacity. Other protein-
aggregate or amyloid-based diseases (like
Alzheimer’s) likely have a nucleating episode in
their pathogenesis, even if there is no means of
contagion from one person to another. At least in
the pancreas, amyloid aggregation is a side effect
of protein injury by glycation (3).
Emerging Pathogens
What are we going to do about new, mutant,
and recombinant pathogen strains? What can we
anticipate about new major outbreaks? How
should we be defending ourselves? The good news
of course is the wonderful technology in the
offing, one marvelous innovation after another in
every field of prophylaxis, vaccines, understand-
ing of pathogenic phenomena. The genomics
work on bacteria is paying off and may even
justify the overall project of human genomics all
by itself with its insights into microbial evolution
and potential targets for new discoveries in
disease management.
At a very high strategic level, we have the
basic knowledge to control foodborne epidemics,
waterborne epidemics, and fecal-borne diseases.
At a technologic level, even sexually transmitted
diseases can be controlled. One neglected
medium is air. Can we do as well in preventing
airborne transmission? Effective control may
come down to something as elementary as a face
mask like that worn by police in 1918. Control of
even a vicious airborne epidemic like influenza
should not be above our technical capability. Tens
or even hundreds of millions of lives might be at
stake over such elementary matters.
The introduction of a new hemolysin into
existing anthrax strains in a demonstration of
their pathogenicity in golden hamsters (4)
required additional epitopes to vaccinate those
hamsters against this anthrax. This first example
of an artificially contrived new human pathogen371 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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illustrates additional challenges in the fight
against emerging infections.
Natural infection and disease are enough of a
challenge and should not be compounded by
human-made agents of death. Biological warfare
cannot be endured and must not be tolerated.
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